ACIP Recommendation for Use of Moderna COVID-19 Vaccine in Adults Aged ≥18 Years and Considerations for Extended Intervals for Administration of Primary Series Doses of mRNA COVID-19 Vaccines

What is already known about this topic?

On January 31, 2022, the Food and Drug Administration (FDA) granted full approval to the Moderna COVID-19 vaccine for persons aged ≥18 years.

What is added by this report?

On February 4, 2022, after a systematic review of the evidence, the Advisory Committee on Immunization Practices issued a standard recommendation for use of the Moderna COVID-19 vaccine in persons aged ≥18 years. CDC provided guidance that an 8-week interval between primary series doses of mRNA vaccines might be optimal for some persons.

What are the implications for public health practice?

Use of the FDA-approved Moderna COVID-19 vaccine is recommended for persons aged ≥18 years; benefits of the prevention of infection and associated hospitalization or death outweigh vaccine-associated risks.